Equity Profile

DNLI

Denali Therapeutics Inc.

Health CareBiotechnology$4.0B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases....

Key Metrics to Watch

Clinical Trial Progress

Updates on ongoing clinical trials are vital as they can influence future revenue and market perception.

N/A

Research and Development Expenses

Investments in R&D are critical for biotech firms, indicating the company's commitment to innovation.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DNLI Q2-2026 Earnings Preview

Context

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. As part of the health care sector, its work is crucial given the growing global concern over conditions like Alzheimer's and Parkinson's disease.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+4.03%

Avg Stock Reaction

-2.80%

Last Quarter Recap

In Q1-2026, Denali reported an EPS of -$0.69, which was better than the expected -$0.73, resulting in a slight positive surprise. However, the stock fell by 3.43% the following day, indicating market skepticism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Denali's upcoming earnings are mixed, with no analyst estimates available. Investors are likely looking for updates on clinical trials and financial health.

Bull Case

If Denali provides positive updates on its clinical trials, it could boost investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company reports higher-than-expected cash burn or delays in trials, it could raise concerns about its financial stability and future prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of ongoing clinical trials?

Investors will closely watch for any advancements or setbacks, as these can significantly impact the company's future revenue potential.

What is the current cash burn rate and how does it compare to previous quarters?

Understanding the cash burn rate is crucial for assessing the company's financial health and sustainability in the long term.

Edge

What the Street Is Missing

Why consensus could be wrong

While the Street may be cautious due to recent cash burn rates, Denali's advancements in clinical trials could be undervalued, leading to a potential upside surprise.

Supporting Evidence

The options market is pricing in a 27.57% move, suggesting expectations of significant volatility.

Denali has a history of beating EPS estimates, which could indicate potential for positive surprises.

Recent trial updates from peers in the biotech sector suggest a favorable environment for clinical advancements.

Key Risk

If the cash burn rate comes in lower than expected, it could shift sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on the balance between clinical progress and financial health, which will determine investor sentiment.

Bull Confirmed If

Positive updates on clinical trials that suggest a higher likelihood of successful outcomes.

Bear Confirmed If

A cash burn rate that exceeds previous quarters significantly, raising concerns about financial sustainability.

Pre-Earnings Positioning

Options Market

Implied Move

±27.57%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±27.6% while DNLI has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

48.7%

Calls (45K)P/C Ratio: 3.33Puts (58K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.7%, with a raw directional average of +3.3% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Denali beats expectations with positive trial updates, history suggests the stock could rise around 4.52% on the first day.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may see muted movement as investors digest the information.

Miss

If the company misses on key metrics, history suggests a potential decline of around 2.88% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for ongoing clinical trials.
2Details on the cash burn rate and financial outlook.
3Any new partnerships or collaborations that could enhance research capabilities.
4Management's perspective on market conditions affecting the biotechnology sector.
5Insights into upcoming product launches or pipeline developments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases....

Key Metrics to Watch

Clinical Trial Progress

Updates on ongoing clinical trials are vital as they can influence future revenue and market perception.

N/A

Research and Development Expenses

Investments in R&D are critical for biotech firms, indicating the company's commitment to innovation.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DNLI Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+4.03%

Avg Stock Reaction

-2.80%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Denali's upcoming earnings are mixed, with no analyst estimates available. Investors are likely looking for updates on clinical trials and financial health.

Bull Case

If Denali provides positive updates on its clinical trials, it could boost investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company reports higher-than-expected cash burn or delays in trials, it could raise concerns about its financial stability and future prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of ongoing clinical trials?

Investors will closely watch for any advancements or setbacks, as these can significantly impact the company's future revenue potential.

What is the current cash burn rate and how does it compare to previous quarters?

Understanding the cash burn rate is crucial for assessing the company's financial health and sustainability in the long term.

Edge

What the Street Is Missing

Why consensus could be wrong

While the Street may be cautious due to recent cash burn rates, Denali's advancements in clinical trials could be undervalued, leading to a potential upside surprise.

Supporting Evidence

The options market is pricing in a 27.57% move, suggesting expectations of significant volatility.

Denali has a history of beating EPS estimates, which could indicate potential for positive surprises.

Recent trial updates from peers in the biotech sector suggest a favorable environment for clinical advancements.

Key Risk

If the cash burn rate comes in lower than expected, it could shift sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on the balance between clinical progress and financial health, which will determine investor sentiment.

Bull Confirmed If

Positive updates on clinical trials that suggest a higher likelihood of successful outcomes.

Bear Confirmed If

A cash burn rate that exceeds previous quarters significantly, raising concerns about financial sustainability.

Pre-Earnings Positioning

Options Market

Implied Move

±27.57%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±27.6% while DNLI has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

48.7%

Calls (45K)P/C Ratio: 3.33Puts (58K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Denali beats expectations with positive trial updates, history suggests the stock could rise around 4.52% on the first day.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may see muted movement as investors digest the information.

Miss

If the company misses on key metrics, history suggests a potential decline of around 2.88% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for ongoing clinical trials.
2Details on the cash burn rate and financial outlook.
3Any new partnerships or collaborations that could enhance research capabilities.
4Management's perspective on market conditions affecting the biotechnology sector.
5Insights into upcoming product launches or pipeline developments.